2. Signaling Pathways
  3. Anti-infection
  4. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV

Related Products

PDF 0.94 MB

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-132306
    CCF0058981
    		Inhibitor 98.02%
    CCF0058981 (CCF981), 3-chlorophenyl analogue, is a noncovalent SARS-CoV-2 3CLpro (SC2) inhibitor with an IC50 of 68 nM. CCF0058981 inhibits SC1 (SARS-CoV-1 3CLpro) with an IC50 of 19 nM. CCF0058981 has antiviral efficacy and has the potential for COVID-19 research.
    CCF0058981
  • HY-P99435
    Amubarvimab
    		Inhibitor
    Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants.
    Amubarvimab
  • HY-N0191R
    Andrographolide (Standard)
    		Inhibitor
    Andrographolide (Standard) is the analytical standard of Andrographolide. This product is intended for research and analytical applications. Andrographolide is a NF-κB inhibitor, which inhibits NF-κB activation through covalent modification of a cysteine residue on p50 in endothelial cells without affecting IκBα degradation or p50/p65 nuclear translocation. Andrographolide has antiviral effects.
    Andrographolide (Standard)
  • HY-151482
    SARS-CoV-2 Mpro-IN-2
    		Inhibitor 98.96%
    SARS-CoV-2 Mpro-IN-2 (compound GC-14) is a selective, low cytotoxic and non-covalent Mpro inhibitor (IC50=0.40 μM) with good anti-SARS-CoV-2 activity (EC50=1.1 μM). SARS-CoV-2 Mpro-IN-2 can be used in COVID-19 studies.
    SARS-CoV-2 Mpro-IN-2
  • HY-16762
    Artefenomel
    		Inhibitor 99.14%
    Artefenomel (OZ439) is an orally active, synthetic anti-malarial compound containing an artemisinin pharmacophore with a mechanism of action similar to that of artemisinin. Artefenomel has antiviral activity against SARS-CoV-2.
    Artefenomel
  • HY-101046
    Azaperone dimaleate
    		Inhibitor 99.87%
    Quipazine dimaleate is a 5-HT agonist with a Ki value of 1.4 nM for displaces [3H]GR65630 from 5-HT3R in rat. Quipazine dimaleate shows antiviral activity against SARS-CoV-2 with an EC50 of 31.64 μM. Quipazine dimaleate behaves as a 5-HT3R antagonist in peripheral models. Quipazine dimaleate can be used for neurological disease research.
    Azaperone dimaleate
  • HY-P99889
    Romlusevimab
    		Inhibitor
    Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
    Romlusevimab
  • HY-19727A
    FOY 251
    		Inhibitor 98.86%
    FOY 251, an anti-proteolytic active metabolite Camostate (HY-13512), acts as a proteinase inhibitor. FOY 251 inhibits SARS-CoV-2 infection in cells assay.
    FOY 251
  • HY-D1270
    Direct Violet 1
    		Inhibitor
    Direct Violet 1, an azo dye, is a textile dye. Direct Violet 1 is also the protein-protein interaction (PPI) between the SARS-CoV-2 spike protein and ACE2 inhibitor with IC50s of 1.47-2.63 μM.
    Direct Violet 1
  • HY-136298A
    X77
    		Inhibitor 99.95%
    X77 is a potent non-covalent inhibitor of the main protease of SARS-CoV-2 (SARS-CoV-2 Mpro). X77 binds to SARS-CoV-2 Mpro with a Kd value of 0.057 μM.
    X77
  • HY-137954
    GRL-0496
    		Inhibitor 99.20%
    GRL-0496 is a potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitor, with an IC50 of 30 nM in both enzyme inhibitory and antiviral assays. GRL-0496 shows SARS-CoV antiviral activity, with an EC50 of 6.9 μM.
    GRL-0496
  • HY-163943
    UNI418
    		Inhibitor 99.61%
    UNI418 is a dual inhibitor of PIKfyve and PIP5K1C with antiviral activity against SARS-CoV-2 (EC50=1.4 μM). UNI418 blocks ACE2-mediated SARS-CoV-2 viral endocytosis by inhibiting PIP5K1C (IC50=60.1 nM; Kd=61 nM). In addition, UNI418 inhibits the proteolytic activation of proteases regulated by PIKfyve (Kd=0.78 nM) to prevent SARS-CoV-2 from entering host cells.
    UNI418
  • HY-153083
    COVID-19 Spike Protein mRNA(N1-Me-Pseudo UTP)
    COVID-19 Spike Protein mRNA will express COVID-19 spike protein, and suitable for detection of RNA delivery, translation efficiency, cell viability, etc. COVID-19 spike protein is the novel coronavirus pneumonia spike protein located on the membrane surface. COVID-19 spike protein undertakes the functions of virus binding to host cell membrane receptors and membrane fusion, thereby mediating the entry of COVID-19 virus into cells. COVID-19 spike protein is an important site of action for host neutralizing antibodies and a key target for vaccine design.
    COVID-19 Spike Protein mRNA(N1-Me-Pseudo UTP)
  • HY-138067
    SSAA09E2
    		Inhibitor 98.37%
    SSAA09E2 is an inhibitor of SARS-CoV (Severe acute respiratory syndrome-Coronavirus) replication, acting by blocking early interactions of SARS-S with the receptor for SARS-CoV, Angiotensin Converting Enzyme-2 (ACE2) .
    SSAA09E2
  • HY-N1913A
    Danshensu sodium
    		Inhibitor 99.9%
    Danshensu (Dan shen suan A) sodium, an orally active phenolic compound, can induce Nrf2/HO-1 activation and inhibition of NF-κB pathway. Danshensu sodium reduces reactive oxygen species (ROS) production, upregulates antioxidant defense mechanism and inhibits intrinsic apoptotic pathway. Danshensu sodium displays a potent antiviral activity against SARS-CoV-2 with EC50 of 0.97 μM. Danshensu sodium has anti-oxidation, anti-apoptosis, anti-lung inflammatory and has the potential for COVID-19, cardiovascular and cerebrovascular diseases research.
    Danshensu sodium
  • HY-139311
    YH-53
    		Inhibitor 98.78%
    YH-53 is a potent 3CLpro inhibitor with Ki values of 6.3 nM, 34.7 nM for SARS-CoV-1 3CLpro and SARS-CoV-2 3CLpro, respectively. YH-53 strongly blocks the SARS-CoV-2 replication. YH-53 is a peptidomimetic compound with a unique benzothiazolyl ketone. YH-53 has the potential for COVID-19 research.
    YH-53
  • HY-14648S
    Dexamethasone-d5
    		Inhibitor 99.86%
    Dexamethasone-d5 is the deuterium labeled Dexamethasone. Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.
    Dexamethasone-d<sub>5</sub>
  • HY-150062
    SARS-CoV-2 nsp3-IN-1
    		Inhibitor ≥98.0%
    SARS-CoV-2 nsp3-IN-1 (Compound 15c) is a Mac1 (SARS-CoV-2 nsp3 macrodomain) inhibitor with the IC50 value of 6.1 μM. SARS-CoV-2 nsp3-IN-1 can inhibit Mac1 ADP-ribosylhydrolase activity. SARS-CoV-2 nsp3-IN-1 demonstrates notable selectivity for coronavirus macrodomains, especially towards SARS-CoV-2 Mac1.
    SARS-CoV-2 nsp3-IN-1
  • HY-15463S1
    Imatinib-d4
    		Inhibitor 99.97%
    Imatinib-d4 is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.
    Imatinib-d<sub>4</sub>
  • HY-14648S3
    Dexamethasone-4,6α,21,21-d4
    		Inhibitor ≥99.0%
    Dexamethasone-4,6α,21,21-d4 is the deuterium labeled Dexamethasone-4,6α,21,21. Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.
    Dexamethasone-4,6α,21,21-d<sub>4</sub>
Cat. No. Product Name / Synonyms Species Source